Pembrolizumab (Keytruda) therapeutic area : classical Hodgkin lymphoma
The purpose of this report is to summarize the evidence regarding the use of pembrolizumab as monotherapy in adult and pediatric patients with refractory or relapsed classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) or who are not candidates for salvage chemothe...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
[Ottawa]
Canadian Agency for Drugs and Technologies in Health
December 2021, 2021
|
| Series: | CADTH reimbursement review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The purpose of this report is to summarize the evidence regarding the use of pembrolizumab as monotherapy in adult and pediatric patients with refractory or relapsed classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) or who are not candidates for salvage chemotherapy and ASCT. Pembrolizumab is an immune checkpoint inhibitor dosed at 200 mg every 3 weeks in adults and 2 mg/kg every 3 weeks in pediatrics |
|---|---|
| Item Description: | "Canadian journal of health technologies, volume 1, issue 12." |
| Physical Description: | 1 PDF file (134 pages) illustrations |